CD19

CD19 molecule

Explore in graph →CI-GENE-00040491HGNC:1633 ENSG00000177455 NCBI 930 CIViC Approved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CD19 delta-ex2, delta-ex5-61
Tisagenlecleucel	B Lymphoblastic Leukemia/LymphomaCURATED_BROADER	Predictive	D	Supports Resistance	4	submitted	EID9700 In an in vitro study, cells transduced with CD19 delta5-6 and CD19 delta2 show significantly no response to CART-19 therapy compared to CD19-FL transduced cells. PMID 26516065 · Sotillo et al., 2015 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (3)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved3 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Hepatocellular Adenoma (INSERM, Cancer Cell 2014) liad_inserm_fr_2014	Hepatocellular Adenoma	Ssm	1	46

Literature

Linked publications (0)

Data not yet available

No publication linked to this gene yet.